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Abstract
Background: CD73 (ecto-5′-nucleotidase) is implicated in the development of many types of cancer. CD73
inhibitors are currently being tested in clinical trials for the treatment of cancer. Understanding the molecular and
cellular actions of CD73 inhibitors is the key to improving this line of therapy.
Methods: Quantitative real-time PCR (qRT-PCR) was used to detect the expression of CD73 and miR-30a-5p;
Western blot and immunohistochemical assays were used to investigate the levels of CD73 and other proteins.
Flow cytometry was used to determine cell cycle stage and apoptosis. CCK-8 and clonogenic assays were used to
investigate cell proliferation. Wound healing, migration and invasion assays were used to investigate the motility of
cells. A lung carcinoma xenograft mouse model was used to investigate the in vivo effects of CD73 and miR-30a-5p.
Results: In the present study, we found that CD73 is overexpressed and miR-30a-5p is underexpressed in
non-small cell lung cancer tissues compared with adjacent noncancerous. Further, we showed that CD73 is a
direct target of miR-30a-5p by luciferase reporter assays, qRT-PCR and western blot analysis. We also found that
overexpression of miR-30a-5p in these non-small cell lung cancer cell lines inhibited cell proliferation in vitro
and in vivo. Moreover, the epithelial-to-mesenchymal phenotype was suppressed and cell migration and invasion were
inhibited; these effects were brought about via the EGF signaling pathway.
Conclusions: Our findings reveal a new post-transcriptional mechanism of CD73 regulation via miR-30a-5p and
EGFR-related drug resistance in non-small cell lung cancer.
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Background
Lung cancer is the leading cause of cancer-related deaths
in China and other countries [1, 2]. Non-small cell lung
cancer (NSCLC) accounts for 85% of lung cancers.
Despite the advances in cancer research and treatment,
the prognosis of NSCLC is still poor, with the 5-year
survival rate being only 15% [3]. Although new drugs
such as gefitinib and erlotinib have been shown to be
beneficial, especially in patients with sensitive target
mutations, the survival and outcome have not changed
dramatically. Therefore, it is important to understand
the pathogenesis of NSCLC and identify new treatment
targets.
Recently, the purinergic signaling pathway, in which
extracellular ATP, ADP and adenosine are the main signal-
ing molecules, has emerged as an important player in can-
cer progression [4]. Purinergic signaling is a multistep
coordinated cascade that involves stimulated release of
ATP/ADP, triggering of signaling events via P2 receptors,
and inactivation of the nucleotide to form adenosine,
which binds to its own activated P1 receptors and influ-
ences cell survival, proliferation and cell motility [5]. Ecto-
5′-nucleotidase (CD73), a component of the purinergic
signaling pathway, is a 70-kD glycosylphosphatidylinositol-
anchored cell surface protein encoded by the NT5E gene
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that plays a crucial role in switching on adenosinergic sig-
naling. CD73 has both enzymatic and non-enzymatic func-
tions in cells [6]: as a nucleotidase, CD73 catalyzes the
hydrolysis of AMP into adenosine and phosphate, and
CD73-generated adenosine plays an important role in
tumor immunoescape [7]; moreover, CD73 also func-
tions as a signal and adhesive molecule that can
regulate cell interaction with extracellular matrix com-
ponents, such as laminin and fibronectin, to mediate
the invasive and metastatic properties of cancers [8, 9].
Both the enzymatic and non-enzymatic functions of
CD73 are involved in cancer-associated processes and
are not completely independent of each other [10].
There is ample evidence to show that CD73 is a key
regulatory molecule in cancer development and is
overexpressed in many cancers, including leukemia,
glioblastoma, melanoma, ovarian cancer, esophageal
cancer, prostate cancer and breast cancer [10]. CD73
expression is also associated with certain clinical char-
acteristics and the prognosis of cancer patients [9,
11–15]. In particular, due to its favorable effects in
tumor-bearing mouse models, which have not been
investigated in the clinic, anti-CD73 therapy is now a
promising approach for cancer treatment in the future
[16, 17]. However, the role of CD73 in lung cancer
remains unclear. Moreover, despite its functional im-
portance, little is known about the transcriptional
regulation of CD73 [18–21].
Studies have shown that the prognosis of cancer is
closely related to the altered expression of miRNAs in
cancer tissues and specific expression signatures or
panels [22], which can also be used to classify human
cancers [23] and distinguish between tumor subtypes
[24]. Recent research has shown that alteration in
miRNA expression may be involved in the regulation of
epithelial-to-mesenchymal transition in tumor progres-
sion [25]. In particular, there is some evidence that miR-
NAs are closely related to the development of human
lung cancer [26, 27]. In our recent study, we used
miRNA arrays to demonstrate the impact of significant
miRNAs on cellular pathways and biological processes,
and showed that miR-30a-5p expression was signifi-
cantly downregulated in NSCLC tissues [28]. To identify
more novel targets of miR-30a-5p that may play a role
in NSCLC, in the present study, we predicted its target
mRNAs using computational algorithms. Interestingly,
miR-30a-5p was one of only two miRNAs that could
bind to the 3′-UTR of CD73 mRNA. Thus, miR-30a-5p
may be involved in the regulation of CD73 in cancer
progression.
Here, we aimed to evaluate the role of CD73 in the
tumorigenesis of NSCLC, and to explore the possible
role of miR-30a-5p in CD73 dysregulation in lung
carcinogenesis.
Results
CD73 is frequently overexpressed in NSCLC tissues
and cell lines
The first goal of this work was to examine the expres-
sion of CD73 protein levels in 24 NSCLC, including 12
adenocarcinoma and 12 squamous cell carcinoma, by
IHC. We found that CD73 is largely located in the cell
membrane and cytoplasm of NSCLC cells (Fig. 1a);
levels of CD73 were high in 15 cases (14/24 = 58.33%).
Further, we analyzed CD73 expression in lysates from 21
freshly harvested tissue samples of NSCLC patients by
western blotting compared with matched noncancerous
tissues. Among 21 randomly selected NSCLC and paired
noncancerous lung tissues, 12 tumors (57.14%) showed
an increase in CD73 protein (Fig. 1b). Moreover, we de-
tected CD73 mRNA expression in 59 paired NSCLC tis-
sues and adjacent noncancerous lung tissues: the CD73
mRNA levels were significantly higher in NSCLC tissues
than adjacent noncancerous lung tissues (Fig. 1c). Add-
itionally, a public data set (Gene Expression Omnibus,
GSE19188) containing 91 NSCLC tissues and 65 normal
lung tissues also showed that CD73 mRNA expression
was upregulated in human NSCLC tissues (Fig. 1d). No
significant difference in the CD73 mRNA level was
observed between NSCLCs when they were classified ac-
cording to age, gender, smoking habit of the patient,
TNM stage and lymph node invasion; however, signifi-
cant differences were observed according to the histo-
logical characteristics (Additional file 1: Table S1). We
used the Kaplan-Meier Plotter online database [29] to
determine the effects of CD73 expression in lung cancer
patients and plotted a Kaplan-Meier survival curve of
NSCLC patients with low or high expression of CD73.
In 227 cases in which neither chemotherapy nor radio-
therapy were performed, high expression of CD73 was
associated with lower survival rates (Fig. 1e). We also
detected CD73 mRNA and protein expression in 10
NSCLC cell lines by qRT-PCR and western blot analysis
(Fig. 1f and g). Thus, CD73 expression was frequently
higher in NSCLC tissues and cell lines than in the nor-
mal cell samples.
Knockdown of CD73 inhibits in vitro cell growth, cell
cycle progression and migration of NSCLC cells
The expression level of CD73 mRNA and protein was
significantly reduced after the stable transfection of
A549 and H226 cells with two CD73 short hairpin RNAs
(shRNAs) (Fig. 2a, Additional file 2: Figure S1). The
CCK-8 assay showed that cell growth was significantly
inhibited in cells with stable knockdown of CD73 com-
pared with the control cells at 48 h and 72 h after trans-
fection (Fig. 2b). We confirmed these findings by
performing a clonogenic assay (Fig. 2c). Moreover, flow
cytometry results indicated that the proportion of cells
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in the G0/G1 phase was significantly higher and the pro-
portion of cells in the S phase was significantly lower in
CD73-silenced cells than in the control cells (P < 0.05,
Fig. 2d and e). These results indicate that CD73 inhibits
cell proliferation in NSCLC cells via its effects on the
cell cycle.
The wound healing assay was performed to observe
the effects of sh-CD73 transfection in NSCLC cells. The
sh-CD73-transfected cells migrated towards the scratch
more slowly than did the control cells (Fig. 2f and g).
Transwell assay of the NSCLC stable cells lines further
indicated that loss of CD73 considerably suppressed the
migratory ability of NSCLC cells (Fig. 2h and i). Thus,
CD73 may have oncogenic roles in NSCLC.
CD73 and its associated pathways may be useful as
therapeutic targets
The specific tyrosine kinase targets of CD73 was
screened using a human RTK phosphorylation array on
CD73 silenced and control A549 cells. The results
showed that phosphorylation of the EGFR family was
downregulated in CD73 silenced cells compared to con-
trol. (Additional file 3: Figure S2 and Additional file 4:
Table S2). Western blots confirmed that phosphorylation
of EGFR was indeed significantly altered in the A549
and H226 cell lines.
Overexpression of CD73 is associated with resistance
to antitumor agents [30, 31]. Additionally, recent studies
have shown that CD73 also affects tumor cells via the
EGFR signaling pathway in breast cancer and colorectal
cancer [11, 32]. EGFR is expressed more abundantly in
malignant than in normal tissue, and in the case of
NSCLC, EGFR expression is higher than that in normal
tissue in 40–80% of the cases [33]. This makes EGFR an
important target for lung cancer therapy. Based on the
literature, we hypothesized that dysregulation of CD73
via the EGFR signaling pathway and knockdown of
CD73 expression can sensitize NSCLC cells to thera-
peutic agents. First, we detected the molecular expres-
sion of EGFR and downstream signaling molecules. As
Fig. 1 CD73 is frequently overexpressed in NSCLC. a Twenty-four formalin-fixed and paraffin-embedded NSCLC tissues were subjected to H & E
staining and IHC analyses of the CD73 protein. Representative images are shown of H & E staining (a & e, i & m), the corresponding CD73 antibody
staining (b–d, f-h and j–l, n-p) in adenocarcinomas and squamous cell carcinomas, respectively. b Western blot analysis of the CD73 protein levels in 21
randomly selected NSCLC tissues and paired noncancerous lung tissues; β-actin was used as an internal control. c CD73 mRNA levels in 59 NSCLC tis-
sues and paired noncancerous lung tissues. d Relative CD73 mRNA expression levels in NSCLC tumors and adjacent normal lung tissues in a public
data set (GSE19188). e Effect of the CD73 expression level on overall survival in 227 lung cancer patients who did not undergo chemotherapy
or radiotherapy was analyzed, and Kaplan-Meier plots were generated using a Kaplan-Meier Plotter (http://www.kmplot.com). f and g The level
of CD73 in human NSCLC cells was detected by qRT-PCR and Western blot, respectively. Abbreviations: N, paired noncancerous lung tissues, T,
non-small cell lung cancer tissues. *P < 0.05
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illustrated in Fig. 3a, our data showed that EGFR, p-
EGFR and p-AKT expression is significantly decreased
in the CD73-silenced cells than in the control cells. Fur-
ther, it was shown that in the stable cell lines with CD73
knockdown, the EGF-induced increase in the p-EGFR
level was inhibited (Fig. 3b).
To explore the effects of knockdown of CD73 on
cell growth, cell cycle progression and migration, and
to determine if these events were mediated by adeno-
sine, we used the CD73 inhibitor APCP and the ad-
enosine analogue NECA. The results showed that
treatment with APCP had a similar effect as sh-CD73
suppression in A549 cells, but had no effect in H226
cells (Additional file 5: Figure S3). Similarly, treatment
with exogenous NECA increased EGFR signaling in
NSCLC cell lines. These results implied that non-
Fig. 2 Silencing of CD73 inhibits NSCLC cell proliferation and motility. a CD73 mRNA and protein levels in stable A549 and H226 cells. b CCK-8
assay of cell viability in NSCLC cell lines; cell viability was determined at 24, 48 and 72 h. c Representative images of clonogenic analysis of cell
proliferation in NSCLC cells. Bar charts showing clonogenic growth of cells. d and e Flow cytometric analysis of NSCLC cell lines (CD73-silenced
cells vs. NC cells). Cells were harvested at 72 h after transfection and stained with propidium iodide. The percentage of cells in each cell cycle
phase is shown in the inset of each panel, in which the values represent the mean ± SD of three measurements. f and g Wound healing assay
was performed to observe the role of CD73-silenced cells, the speed with which cells migrated towards the scratch was lower in sh-CD73-transfected
cells than in control cells. h and i CD73 silencing inhibits invasion and migration of NSCLC cells. CD73-silenced NSCLC cells were allowed to migrate
through an 8-μM pore Transwell. The cells that migrated were stained and counted in at least three microscopic fields (magnification, ×100). Then, the
cells were treated as above and allowed to invade through the Matrigel-coated membrane in Transwells. Invasive cells were stained and counted
under a light microscope. *P < 0.05; **P < 0.01; ***P < 0.001
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enzymatic functions of CD73 are important in H226
cells.
In the A549 stable cell line, the viability of the cells
decreased by 50% when they were exposed to gefitinib
(P < 0.001, Fig. 3d). Similar synergistic effects were not
observed when the cells were exposed to lapatinib com-
pared with gefitinib (Fig. 3c). In the H226 stable cell
line, the viability of cells was reduced by approximately
30% in response to gefitinib and lapatinib (Fig. 3e and f);
significant changes were not observed in control NSCLC
cells exposed to gefitinib or lapatinb (Additional file 6:
Figure S4). Our data seem to indicate that CD73 inhib-
ition could improve the clinical effects of EGFR-TKI,
especially in squamous cell lung carcinoma.
miR-30a-5p expression is downregulated in NSCLC tissues
and cell lines
miR-30a-5p expression is significantly downregulated in
NSCLC tissues (Additional file 7: Table S3) [28]. This af-
fects crucial cellular pathways, including cell-cell adhe-
sion and signaling, cell cycle regulation and apoptosis,
and plays a significant role in the pathogenesis of
NSCLC (Additional file 8: Figure S5). Among the 59
randomly selected paired tissues from NSCLC patients,
miR-30a-5p expression was found to be significantly re-
duced in tumor tissues when compared with paired non-
cancerous tissues (Fig. 4a, and Additional file 1: Table
S1). Further, a public dataset (GSE36681) containing 47
NSCLC tissues and 47 normal lung tissues showed that
miR-30a-5p expression was downregulated in human
NSCLC tissues (Fig. 4b). Moreover, we examined CD73
mRNA expression in eight NSCLC cell lines (Fig. 4c)
and found that miR-30-5p levels in lung squamous car-
cinoma cell lines (H226 and H520) was lower than in
lung adenocarcinoma cell lines in general.
Ectopic miR-30a-5p reduces CD73 expression by targeting
the CD73 3′-UTR in NSCLC cells
We used bioinformatics analysis to identify additional
novel targets of miR-30a-5p, and found that miR-30a-5p
is one of only two miRNAs that could bind to the 3′-
UTR of CD73 mRNA (TargetScanHuman: http://
www.targetscan.org/). Therefore, it is possible that miR-
30a-5p inhibits CD73 expression by directly binding to
its 3′-UTR region (Fig. 4d). To confirm that CD73 ex-
pression is directly regulated by miR-30a-5p, we sub-
cloned the CD73 3′-UTR containing the miR-30a-5p
binding site (wild type/mutant type) into the psiCHECK-
2 vector (Fig. 4e). We transiently cotransfected the
reporter construct with the miR-30a-5p mimics or in-
hibitor into A549 and H226 cells. The results showed
that miR-30a-5p significantly inhibited luciferase activity
in cells transfected with the wild-type CD73 3′-UTR but
did not repress luciferase activity in cells containing the
mutant construct (Fig. 4f and g).
In addition, we detected CD73 expression in A549 and
H226 cells transfected with miR-30a-5p and its inhibitor,
respectively, while the control cells were transfected with
miR-NC. The data showed that the expression of miR-
Fig. 3 CD73 knockdown increased the sensitivity of NSCLC cells to
gefitinib and lapatinib. a The expression of proteins in the CD73 and
EGFR signaling pathways was detected in the stable A549 and H226
cell lines. Our data showed that p-EGFR and p-AKT expression is
significantly decreased in CD73-silenced cell lines compared with
the control cells. b After serum starvation for 24 h, CD73-silenced
A549 and H226 cells were treated with or without EGF (50 ng/ml)
for 30 min. The expression levels of CD73, p-EGFR, EGFR, p-AKT,
AKT, p-ERK and ERK were analyzed by western blot analysis. c–f
CD73 knockdown increased the sensitivity of NSCLC cells to gefitinib
and lapatinib. The A549 and H226 cell lines were transfected with
10 μM gefitinib and 20 μM lapatinib for 48 h, respectively. After the
aforementioned treatments, cell viability was assessed using CCK-8
assays. The data shown represent the mean ± SD values of four
replicate experiments. All the data were obtained from three independent
experiments and are shown as the mean± SD values. **P 0.01; ***P< 0.001
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Fig. 4 (See legend on next page.)
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30a-5p is increased in NSCLC cells transfected with the
miR-30a-5p mimics compared with the cells transfected
with miR-NC (Fig. 4h). Moreover, the expression of
miR-30a-5p was lower in NSCLC cells transfected with
the miR-30a-5p inhibitor than in cells transfected with
miR-NC (Fig. 4k), In line with the expression of miR-
30a-5p, the level of CD73 was downregulated or upregu-
lated, as determined using qRT-PCR and western blot
analysis (Fig. 4i–m).
Overexpression of miR-30a-5p can inhibit NSCLC cell
proliferation and migration
Furthermore, to determine the function of miR-30a-5p
in NSCLC, we induced overexpression of miR-30a-5p by
using miR-30a-5p mimics and silencing miR-30a-5p
using the miR-30a-5p inhibitor in NSCLC cells and
studied the effects on cell growth. CCK-8 assays showed
that NSCLC cells overexpressing miR-30a-5p had signifi-
cantly lower proliferation ability than the control cells
(Fig. 5a and b). In contrast, silencing of miR-30a-5p re-
sulted in a significantly higher proliferation rate than ob-
served in the control cells, with the exception of the
H226 cell lines (Fig. 5b).
The wound healing assay was performed to observe
the role of miR-30a-5p transfection in A549 and H226
cells. As shown in Fig. 5c, the speed with which cells mi-
grated towards the scratch was lower in the cells trans-
fected with the miR-30a-5p mimics than in the control
cells. Transwell assay of A549 and H226 cells further in-
dicated that loss of miR-30a-5p considerably suppressed
the migratory ability of NSCLC cells (Fig. 5d). Taken to-
gether, these observations suggest that miR-30a-5p may
have tumor suppresser functions in NSCLC.
In line with the results for CD73-silenced cells, our
data showed that p-EGFR and p-AKT show significantly
lower overexpression in the miR-30a-5p-overexpressing
cell lines than in the control cells (Fig. 5e). In contrast,
miR-30a-5p silencing led to higher p-AKT expression
than in the control cells. These findings were not ob-
served in the H226 cell lines, but this result is in line
with the findings of the CCK-8 assay in which the miR-
30a-5p inhibitor was used (Fig. 5f ).
CD73 knockdown in NSCLC cells inhibits tumor growth
via overexpression of miR-30a-5p in nude mice
To clarify the cellular mechanisms underlying miR-30a-
5p-mediated tumor suppression, control A549 sh-NC
cells and the corresponding stable CD73-silenced cells
were inoculated into BALB/C athymic mice. As shown
in Fig. 6a and b, tumors formed by the CD73-silenced
cells were smaller in size and weight than those formed
from the control cells. The tissues resected from the
xenograft tumors were analyzed to verify CD73 and
EGFR expression using qRT-PCR and IHC (Fig. 6c and d).
As miR-30a-5p is significantly downregulated in
NSCLC, an miR-30a-5p agomir was used for replacement
therapy. As shown in Fig. 7c and d, the miR-30a-5p ago-
mir resulted in a significant increase in the expression of
miR-30a-5p and a significant decrease in the expression of
CD73, and the tumors treated with the miR-30a-5p ago-
mir were smaller in size and weight than the control tu-
mors (Fig. 7a and b). These findings are consistent with
those in the previous paragraph. Moreover, the resected
tissues from the treated xenograft tumors were analyzed
to verify EGFR and CD73 expression using IHC (Fig. 7e).
All these findings indicate that repression of CD73 could
inhibit lung cancer cell growth in vivo, and that this mech-
anism is regulated by miR-30a-5p.
Discussion
The findings of the present study indicate that CD73 is a
critical factor in the tumorigenesis of NSCLC and that
its mechanism involves the EGFR signaling pathway.
This finding is consistent with the results of studies on
other cancer types [11, 32].
miR-30a has been found to be one of the miRNAs that
are downregulated in various types of solid tumors, in-
cluding ovarian cancer, colon cancer, prostate cancer,
myeloma cells and lung cancer [34–36]. Further, in an
elegant study conducted by Cheng et al., miR-30a was
found to be significantly downregulated in the primary
tumor of patients with metastatic cancer; this implies
that miR-30a has some putative function in cancer and
potentially metastasis [37]. However, the tumor sup-
pressive role of miR-30a is poorly understood. In the
present study, we have reported for the first time that
(See figure on previous page.)
Fig. 4 miR-30a-5p expression is decreased in NSCLC, and miR-30a-5p directly targets the 3′-UTR of CD73 to decrease CD73 expression. a Relative
miR-30a-5p levels in 59 NSCLC tissues (T) and paired noncancerous lung tissues (N). b Scatter diagram showing relative CD73 mRNA expression
in NSCLC tumors and adjacent normal lung tissues from a public data set (GSE36681). c qRT-PCR analysis of relative miR-30a-5p expression in
human NSCLC cell lines. d Schematic diagram showing the subcloning of the predicted miR-30a-5p binding site at two positions (328–355 and
1442–1449) of the CD73 3′-UTR into a psiCHECK-2 luciferase construct. Predicted duplex formation between miR-30a-5p and the wild-type or
mutant miR-30a-5p binding site is indicated. e–g Luciferase activity of the construct containing the wild-type or mutant CD73 3′-UTR reporter
gene in A549 and H226 cells co-transfected with the negative control (NC) or miR-30a-5p. Scrambled sequences were used as the NC. Relative
Renilla luciferase activity was determined and normalized against firefly luciferase activity. h–j and k–m Expression of miR-30a-5p and CD73 in
NSCLC cells transfected with miR-30a-5p mimics or inhibitor was detected by qRT-PCR and western blot analysis respectively. *P < 0.05;
**P < 0.01; ***P < 0.001
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miR-30a-5p plays an important role in the suppression
of cell proliferation, migration and invasion in NSCLC
via its effects on CD73 gene expression both in vitro
and in vivo.
In the present study, we detected the expression of
CD73 in NSCLC tissues and cell lines. CD73 expression
was upregulated in NSCLC tissues compared with
matched paracancerous tissues. Moreover, we identified
the expression of CD73 in the NSCLC cell lines exam-
ined, which shows that CD73 is frequently overexpressed
in NSCLC. Our findings indicate that shRNA-induced
knockdown of CD73 significantly inhibits NSCLC cell
proliferation by repressing the NSCLC cell cycle. The
co-expression of CD73 and EGFR has been reported in
other types of cancers [11, 32]. Consistent with the pre-
vious findings, in the present study too, CD73 was found
to promote EGFR expression. However, the interactions
and underlying mechanisms need to be elucidated.
Therefore, our findings demonstrated that CD73 may
play a tumor-promoting role in NSCLC via its effects on
EGFR signaling.
Although there is ample evidence for the upregulation
of CD73 expression in human cancers, the underlying
mechanisms are poorly understood. In this study, we fo-
cused on NSCLC cells and tissues to determine whether
miRNAs can epigenetically influence CD73 expression.
Intriguingly, the miR-30a-5p level was found to be re-
duced in NSCLC cells and tissues, which is in line with
the findings of other studies [36, 38]. The results imply
that miR-30a-5p functionally contributes to the expres-
sion of CD73 in NSCLC. Although several miRNAs, in-
cluding miR-30a-5p, have been implicated in prostate
cancer, myeloma cells and lung cancer, the targets of
miR-30a-5p have not yet been identified [36]. Therefore,
in the present study, we performed in silico prediction
of microRNA targets and found that miR-30a-5p can
Fig. 5 Overexpression of miR-30a-5p inhibits NSCLC cell proliferation and motility. a & b CCK-8 assay of cell viability in NSCLC cell lines transfected
with miR-30a-5p mimics or miR-30a-5p inhibitor at 24, 48 and 72 h. c A wound healing assay was performed to observe the role of miR-30a-5p
transfection in cells. The data showed that the speed with which the cells migrated towards the scratch was lower in cells transfected with the
miR-30a-5p overexpression vector than in the control cells. d Overexpression of miR-30a-5p inhibits invasion and migration of NSCLC cells. The
A549 and H226 cell lines were transfected with miR-30a-5p mimics and allowed to migrate through 8-μM pore Transwells. The cells that
migrated were stained and counted in at least three microscopic fields (magnification, ×100). Then, cells were treated as described before and
allowed to invade through the Matrigel-coated membrane in Transwells. The invasive cells were stained and counted under a light microscope.
e and f The A549 and H226 cells were treated with or without miR-30a-5p mimics or the miR-30a-5p inhibitor for 72 h, respectively. The expres-
sion levels of p-EGFR, EGFR, p-AKT, AKT, p-ERK, ERK and Cyclin D1 were analyzed by western blotting. **P < 0.01; ***P < 0.001
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potentially bind to two target sites of CD73 3′-UTR, and
that miR-30a-5p is one of only two such molecules that
can bind to the 3′-UTR of CD73 mRNA. Next, we used
two methods to confirm whether CD73 is a bona fide
target of miR-30a-5p. First, a luciferase reporter assay
was performed, and it showed that miR-30a-5p can se-
lectively target two putative site of the CD73 3′-UTR.
Second, ectopic expression of miR-30a-5p in NSCLC
cells was examined and found to be significantly re-
duced, and CD73 mRNA and protein expression was
found to have increased. This provides a strong rationale
for our findings that both low miR-30a-5p and high
CD73 expression are found in NSCLC.
It is known that miR-30a-5p is frequently downregu-
lated in human cancer tissues [35, 38] as well as in hu-
man epithelia-derived cancer cells [37]. Our present data
showed that CD73 is required for NSCLC cell prolifera-
tion (Fig. 2). These findings together seemed to indicate
the possibility that miR-30a-5p may inhibit NSCLC cell
proliferation. As expected, ectopic miR-30a-5p expres-
sion was found to inhibit NSCLC cell proliferation and
migration in NSCLC cells, which further confirms the
tumor-promoting function of CD73. However, we can-
not exclude the possibility that miR-30a-5p may have
different functions, may be even tumor-inhibiting func-
tions, in other types of cancer, because a single miRNA
Fig. 6 CD73 promotes tumor growth in vivo. a CD73-silenced A549 cell xenografts in nude mice (n = 6) at the experimental endpoint; tumors
were dissected and photographed as shown. Tumor growth curves in mice (n = 6 in each group) inoculated with the indicated cells at the
indicated days; b Each tumor formed was weighed. c CD73 mRNA expression in tumors was detected by qRT-PCR analysis. d Hematoxylin and
eosin (H & E) staining confirmed the presence of tumor cells in slices of the indicated tumor sections. Immunohistochemical staining for CD73
and EGFR was quantified based on staining intensity. *P < 0.05; **P < 0.01
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may have different functions in different cellular con-
texts [39].
A considerable amount of evidence suggests that miR-
NAs play a role in fighting drug resistance. Overexpres-
sion of CD73 is also associated with resistance to
antitumor agents. Further, some studies have shown the
therapeutic potential of CD73 blockade for cancer ther-
apy [40–42], and the effects of CD73 on tumor cells via
the EGFR signaling pathway [11, 32]. In keeping with all
these previous findings, we found that shRNA-mediated
Fig. 7 a miR-30a-5p inhibits tumor growth by targeted CD73 in vivo. At the experimental endpoint, tumors treated with the miR-30a-5p agomir
were dissected and photographed as indicated. Tumor growth of A549 xenografts in nude mice treated with the miR-30a-5p agomir and NC
agomir (n = 3). The graph shows the tumor growth curves at the time of sacrifice with respect to the first measurements, after the administration of
2 nmol miR-30a-5p agomir or NC agomir per mouse seven times every 4 days; the arrows indicate the weight of the excised tumors (mean ±
SD, n = 3). b Each tumor formed by the indicated cells was weighed. c and d qRT-PCR analysis of miR-30a-5p levels and CD73 mRNA expression in
excised tumors transfected with the miR-30a-5p agomir and NC agomir; U6 and β-actin were used as internal controls, respectively. e Hematoxylin
and eosin (H & E) staining confirmed the presence of tumor cells in slices of the indicated tumor sections. Immunohistochemical staining for CD73
and EGFR was quantified based on staining intensity. *P < 0.05; **P < 0.01
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CD73 knockdown increased the sensitivity of NSCLC
cells to gefitinib and lapatinib.
It was recently reported that EGFR signaling is
coupled with activation of cap-dependent translation in
NSCLC cells expressing wild-type EGFR [11]. Resistance
to EGFR-TKI can be mediated through multiple signal-
ing pathways that converge upon cap-dependent transla-
tion in NSCLC cells expressing wild-type EGFR.
Interestingly, our present study showed that CD73 af-
fected the efficacy of EGFR-targeted therapies in NSCLC
cells with wild-type EGFR. Thus, future investigation
into the molecular mechanisms of CD73-mediated drug
resistance could help develop novel CD73-based thera-
peutic agents to improve the treatment of NSCLC.
Conclusions
Taken together, these results are the first to report that
CD73 expression is upregulated in NSCLC and is corre-
lated with a decrease in miR-30a-5p expression. Further,
we found that miR-30a-5p inhibits CD73 expression by
directly targeting CD73 3′-UTR, and thereby represses
NSCLC cell proliferation. Thus, our findings shed light
on the mechanistic interaction between miR-30a-5p and
CD73 in NSCLC carcinogenesis. This miR-30a-5p-medi-
ated downregulation of CD73 provides new insight into
therapy strategies for NSCLC.
Methods
Tissue samples
Fifty-nine paired NSCLC tissues and adjacent noncan-
cerous lung tissues were collected, with the informed
consent of the patients from the First Affiliated Hospital
of Soochow University between 2009 and 2013. The pa-
tients had been diagnosed with NSCLC based on their
histological and pathological characteristics according to
the Revised International System for Staging Lung
Cancer. They had not undergone chemotherapy or
radiotherapy prior to tissue sampling. The tissue samples
were snap-frozen and stored in a cryofreezer at −80 °C.
This study was approved by the Academic Advisory
Board of Soochow University.
Cell culture
Human NSCLC cell types A549, H1650 and SPC-A1
(lung adenocarcinoma cell lines) and H460 (giant-cell
lung carcinoma cell line), 95C, 95D and H226, H520
(lung squamous carcinoma cell line) were purchased
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). The cells were grown in RPMI 1640
medium containing 10% fetal bovine serum (FBS)
(Gibco, Carlsbad, CA, USA) and L-glutamine (Invitro-
gen, Carlsbad, CA, USA) at 37 °C in a humidified atmos-
phere containing 5% CO2. Genetic characteristics of the
cells were determined by the Beijing Microread Genetics
company using a Goldeneye™ 20A Kit and ABI 3100. All
cell lines were passaged for less than 3 months and
tested in January 2016.
Immunohistochemical assay
Immunohistochemical (IHC) analyses of tissues were
conducted as described in our previous study [43]. In
brief, sections were incubated with EGFR (A-10) and
CD73 (IE9) specific monoclonal primary antibodies (di-
luted 1:100; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4 °C, then incubated with biotinylated
secondary antibodies. The reactions were developed
using the DAB Kit (BD Bioscience, San Jose, CA, USA)
and the sections were counterstained with hematoxylin.
RNA extraction and quantitative real-time PCR analysis
RNA isolation, cDNA synthesis and quantitative reverse
transcription–PCR analysis were performed as previ-
ously described [28]. The primer sequences used for
CD73 mRNA detection were 5′-TCTTCTAAACAG-
CAGCATTCC-3′ (forward) and 5′-CATTTCATCCGT
GTGTCTCAG-3′ (reverse). Ct values for CD73 mRNA
and miR-30a-5p were equilibrated to ACTB mRNA and
U6, respectively, which were used as internal controls.
The △△Ct method was applied to calculate the relative
expression of these proteins.
Kinase and Western blot assays
5′-(N-Ethylcarboxamido) adenosine (NECA, E2387) and
Adenosine 5′-(α, β-methylene) diphosphate (APCP,
M3763) were purchased from Sigma. Cells were seeded
into 6-well plates at a concentration of 30 × 104 cells/
well. After 24 h, cells were treated with NECA (1 μM)
for 24 h or APCP (10 μM) for 1 h, then were harvested
and lysed in RIPA buffer (Cell Signaling Technology,
Danvers, MA, USA) containing a protease and phos-
phatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO,
USA).
For the human receptor tyrosine kinase (RTKs) assay,
we used the phosphorylation antibody array-AAH-
PRTK-1 (RayBiotech Inc.). Protein lysates were incu-
bated with the array membrane and protein signal was
visualized using a chemifluorescence detection system
(Bio-Rad) according to the manufacturer’s protocol.
Relative density of specific protein expression was deter-
mined using Quantity One software.
Western blot analysis was performed as previously de-
scribed [43]. The antibodies used in the analysis were
anti-CD73 (D7F9A), anti-pEGFR (Tyr1068, 1H12), anti-
pAKT (Ser473, D9E), anti-AKT, anti-pERK (Thr202/204,
D13.12.4E), anti-ERK (137 F5), anti-pFak (Tyr397,
D20B1), anti-FAK (D2R2E) and anti-CyclinD1 (92G2, all
from Cell Signaling Technology, Danvers, MA, USA),
anti-EGFR (A-10, Santa Cruz, CA, USA), anti-β-actin
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and anti-mouse or anti-rabbit secondary antibodies (Cell
Signaling Technology).
Plasmids construction, transient transfection and
luciferase assay
To construct a plasmid containing the CD73 3′-untrans-
lated region (3′-UTR) fused to the 3′-end of a luciferase
reporter, 1746-bp sequences containing the predicted
miR-30a-5p target sites were synthesized and ligated into
the pGL3-control vector (Promega, Madison, WI, USA).
CD73 3′-UTR was amplified with the primers 5′-
GGCTAGTCTAGACTGCCTTTTAGGACCTGGCT-3′
(forward) and 5′-GGCTAGTCTAGA ACCGAGGCTA
TTATTTTGCTGC-3′ (reverse) and were subcloned
into a pGL3 control vector with the restriction endo-
nuclease XbaI site (italic font) to generate pGL3-CD73-
3′-UTR. The 3′-UTR of CD73 containing two putative
miR-30a-5p-binding sites was amplified and cloned into
a pGL3-control vector separately. In the mutated frag-
ment, four mutational bases were introduced into the
predicted miR-30a-5p target sites. The wild-type and
mutated fragments were directly synthesized (Genewiz,
Suzhou, China), digested with XbaI and subcloned into
the pGL3-control vector. Subsequently, cells were
seeded into 24-well plates and co-transfected with the
constructed plasmid, the pRL-TK plasmid and with ei-
ther miR-30a-5p mimics or miR-NC; miR-30a-5p inhibi-
tor and matched NC were purchased from RiboBio Co.,
Ltd (Guangzhou, China). After 48 h, cells were collected
and their luciferase activity was measured using the
Dual-Luciferase Reporter Assay Kit (Promega). The re-
sults are expressed as the relative firefly luciferase activ-
ity, which is obtained after normalization to Renilla
luciferase activity. All the transient transfections, includ-
ing the miR-30a-5p mimic, inhibitor and miR-NC trans-
fections, were performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA).
Establishment of CD73-silenced stable cell lines
To establish stable cell lines with silenced CD73 expres-
sion, two DNA fragments (CD73 shRNA-1, 5′-GATCCG
GAATCGTTGGATACACTTCCTTCAAGAGAGGAAG
TG TATCCAACGATTCCTTTTTTG-3′; CD73 shRNA-
2, 5′-GATCCGCCGCTTTAGAGAATG CAACATTCAA
GAGATGTTGCATTCTCTAAAGCGGCTTTTTTG-3′)
were subcloned into the lentiviral vector pGLV2-U6-Puro
(GenePharma, Shanghai, China) containing the endonu-
cleases AgeI and EcoRI. A scrambled sequence (under-
scored) of CD73 shRNA, which served as the negative
control, was used: 5′-GATCCGTTCTCCGAACGTGT-
CACGTT TCAAGAGAACGTGACACGTTCGGAGAA
CTTTTTTG-3′. Then, the CD73-silenced construct or
negative control was co-transfected with packaging plas-
mids into human embryonic kidney 293 T cells using
Lipofectamine 2000 (Invitrogen). After 48 h, cells were in-
fected with the packaged lentiviruses and cultured for
2 days before being selected with 0.4 μg/ml and 2 μg/ml
of puromycin, respectively (Sigma-Aldrich, St Louis, MO,
USA).
Cell proliferation analysis and drug treatment
Cell proliferation was examined using Cell Counting
Kit-8 (Boster, Wuhan, China). Cells or the corresponding
negative control cells were seeded in 96-well plates at a
density of 2 × 103 cells per well and further grown under
normal culture conditions for 24, 48 and 72 h. Cell via-
bility was determined according to the manufacturer’s
instructions. The experiment was performed in tripli-
cate. We also detected cell proliferation using a clono-
genic assay. In brief, cells transfected with miR-30a-5p
mimics and sh-CD73 or sh-NC were suspended in
complete culture medium and 200 cells were reseeded
into a 60 mm plate. After incubation for 14 – 20 days,
foci of least 50 cells were stained with Giemsa and
counted. Cell viability was measured according to manu-
facturer’s instructions at several time points (24, 48 and
72 h). Each experiment was performed in triplicate. For
drug treatment, stable CD73-knockdown cells were
plated into 96-well plates, and gefitinib and laptinib (ge-
fitinib C#s1025, laptinib C#s2111, Selleck Chemicals,
Houston, TX, USA) were added to the cultures. Cell via-
bility was assessed 72 h after the drug treatment.
Wound healing, migration and invasion assays
The motility of cells was analyzed as previously de-
scribed [43]. For the wound healing assay, cells were
seeded into 6-well plates and cultured for 48 h to form a
monolayer. The monolayer was then scratched with a
new 10-μl pipette tip across the center of the well,
washed gently twice with PBS and replenished with
fresh medium. The cells were grown for an additional
24 h and were visualized on a microscope (CKX41,
Olympus).
For the migration assay, 5 × 104 cells in medium
containing 1% FBS were seeded into the upper cham-
ber of a Transwell insert, 800 μl medium containing
10% FBS was into the lower chamber and then incu-
bated at 37 °C for 24 h, according to the manufac-
turer’s instructions. For the invasion assay, the inserts
were coated with the Matrigel matrix (BD Science,
Sparks, MD, USA) and cells were diluted in serum-
free medium before plating and incubated at 37 °C
for 2 h. In both assays, the cells were then photo-
graphed and counted.
Cell cycle analysis
According to the instructions of the Cell Cycle Analysis
kit (Beyotime, Shanghai, China), cells were cultured in
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6-well plates. The cells were collected, washed with cold
PBS, fixed in 70% ethanol at 4 °C for 24 h, washed with
cold PBS again, and stained with a propidium iodide
(PI)/RNase A mixture. The cells were then kept in the
dark at 37 °C for 30 min and analyzed with a
fluorescence-activated cell sorting (FACS) caliber system
(Beckman Coulter, Brea, California).
Animal experiments and immunocytochemistry staining
Female BALB/c athymic nude mice (4–6 weeks old
and weighing 16–20 g) were purchased from the Ex-
perimental Animal Center of Soochow University and
bred under pathogen-free conditions. All the animal
experiments were carried out in accordance with the
Guide for the Care and Use of Experimental Animals
Center of Soochow University. To establish the lung
carcinoma xenograft model, A549 cells and stable
CD73-knockdown A549 cells were suspended in
100 ml PBS and inoculated subcutaneously into the
flanks of nude mice. After 8–10 days, the nude mice
with transplanted A549 cells were randomly divided
into two groups (8 mice in each group). The mice
with transplanted CD73-knockdown A549 cells were
also split into two groups. An miR-30a-5p agomir and
NC agomir (RiboBio Co. Ltd., Guangzhou, China)
were directly injected into the A549 implanted tu-
mors at a dose of 2 nmol (in 20 μl PBS) per mouse
every 4 days seven times (28 days total). Chemically
stabilized miRNAs may have markedly improved
pharmacological properties, as described before [44].
Tumor volume (V) was determined by measuring the
length (L) and width (W) with a vernier caliper and
applying the formula V = (L ×W2) × 0.5.
Statistical analysis
Differences in CD73 and miR-30a-5p expression be-
tween NSCLC tissues (T) and adjacent noncancerous
lung tissues (N) were analyzed using a paired t-test
(two-tailed). For cell lines, differences between two
groups were assessed using an unpaired t-test (two-
tailed). The clinicopathologic characteristics and ex-
pression levels of mRNA and miRNA in the NSCLC
samples were compared using nonparametric tests
(Mann–Whitney U-test for comparison between two
groups, and the Kruskall-Wallis test for comparison
between three or more groups). Two-way ANOVA
was used to determine the difference in cell growth
between two groups. Differences were considered to
be significant at P < 0.05. All statistical analyses were
performed using GraphPad Prism 5.02 (GraphPad,
San Diego, CA, USA) and the SPSS 16.0 software
(SPSS, Chicago, IL, USA).
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Additional file 3: Figure S2. Human RTK phosphorylation array. The
specific kinase target of CD73 was screened using a human RTK
phosphorylation array, including 71 RTKs, with both CD73 silenced and
control A549 cells. The results showed that phosphorylation of the EGFR
family was downregulated in both CD73 silenced cells compared with
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Additional file 4: Table S2. Signal densities of human RTK
phosphorylation array. (DOCX 20 kb)
Additional file 5: Figure S3. Effects of the CD73 inhibitor APCP and
the adenosine analogue NECA in NSCLC cell lines. Cells were seeded into
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with NECA (1 μM) for 24 h or APCP (10 μM) for 1 h, before being harvested
and lysed in RIPA buffer. The results showed that inhibitor APCP functioned
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transfected with Mock and sh-NC to gefitinib or lapatinb. Mock trans-
fected cells were treated without vector or plasmid. The drug treatment
control had drug replaced by DMSO alone. (TIF 386 kb)
Additional file 7: Table S3. Differential expression of miRNAs and miR-
30a-5p is downregulated in NSCLC. (DOC 57 kb)
Additional file 8: Figure S5. Pathway and Gene Ontology Affected.
Pathway analysis was used to identify the significant pathway of the
differential genes according to the KEGG database. The Fisher’s exact test
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